698091001: Canakinumab (substance)

SNOMED CT Concept\Substance\...

\Substance categorized by disposition\Substance with receptor antagonist mechanism of action (substance)\Interleukin receptor antagonist\Interleukin 1 receptor antagonist\Canakinumab (substance)
\Substance categorized by disposition\Immunomodulator\Interleukin receptor antagonist\Interleukin 1 receptor antagonist\Canakinumab (substance)

\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Immunologic agent (substance)\Canakinumab (substance)
\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Monoclonal antibody\Canakinumab (substance)

\Substance categorised by structure\Chemical\Chemical categorized by structure (substance)\...

\Nitrogen and/or nitrogen compound (substance)\Nitrogen compound\Organic nitrogen compound\Amide and/or amide derivative (substance)\Substituted amide (substance)\Polypeptide\Protein\Antibody\Monoclonal antibody\Canakinumab (substance)

\Organic compound\Organic nitrogen compound\Amide and/or amide derivative (substance)\Substituted amide (substance)\Polypeptide\Protein\Antibody\Monoclonal antibody\Canakinumab (substance)

\Biological substance\Protein and/or protein derivative\Protein\Antibody\Monoclonal antibody\Canakinumab (substance)
\Biological substance\Immunologic substance\Antibody\Monoclonal antibody\Canakinumab (substance)
\Biological substance\Polypeptide\Protein\Antibody\Monoclonal antibody\Canakinumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2014. Module: SNOMED CT core

Descriptions:

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Canakinumab (substance)	Is a	agent d'anticorps monoclonal	false	Inferred relationship	Some
Canakinumab (substance)	Is a	Interleukin 1 receptor antagonist	true	Inferred relationship	Some
Canakinumab (substance)	Is a	Monoclonal antibody	true	Inferred relationship	Some
Canakinumab (substance)	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Interleukin 1 receptor antagonist (disposition)	true	Inferred relationship	Some
Canakinumab (substance)	Is a	Immunologic agent (substance)	true	Inferred relationship	Some

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
Product containing canakinumab (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Canakinumab (substance)	Inferred relationship	Some	1
Canakinumab 150mg powder for injection solution	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Canakinumab (substance)	Inferred relationship	Some
Canakinumab only product	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Canakinumab (substance)	Inferred relationship	Some	1
Canakinumab-containing product in parenteral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Canakinumab (substance)	Inferred relationship	Some	1
Product containing precisely canakinumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Canakinumab (substance)	Inferred relationship	Some	1
Product containing precisely canakinumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Canakinumab (substance)	Inferred relationship	Some	1
Product containing precisely canakinumab 150 milligram/1 vial lyophilized powder for conventional release solution for injection (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Canakinumab (substance)	Inferred relationship	Some	1
Product containing precisely canakinumab 150 milligram/1 vial lyophilized powder for conventional release solution for injection (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Canakinumab (substance)	Inferred relationship	Some	1
Canakinumab only product in parenteral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Canakinumab (substance)	Inferred relationship	Some	1
Canakinumab 150 mg powder for solution for injection vial	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Canakinumab (substance)	Inferred relationship	Some	1
Canakinumab 150 mg powder for solution for injection vial	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Canakinumab (substance)	Inferred relationship	Some	1
Canakinumab therapy (procedure)	Direct substance	True	Canakinumab (substance)	Inferred relationship	Some	1

This concept is not in any reference sets

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
2971724019	Canakinumab (substance)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
2971764015	Canakinumab	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
50941000195111	canakinumab	it	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
797311000172110	canakinumab	fr	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
65071000195116	Canakinumab	de	Synonym (core metadata concept)	Active	Entire term case sensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module